Page last updated: 2024-12-06

almitrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Almitrine is a synthetic, selective, and potent respiratory stimulant that acts by stimulating peripheral chemoreceptors located in the carotid and aortic bodies. Its mechanism of action involves increasing the sensitivity of these chemoreceptors to hypoxia, leading to an increase in ventilation. Almitrine is used clinically as a treatment for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It is known to improve pulmonary function, reduce breathlessness, and enhance exercise tolerance in patients with COPD. While almitrine has shown efficacy in treating respiratory conditions, its use has been limited due to potential side effects, such as hypertension and palpitations. Research continues to explore the potential benefits and risks of almitrine and to investigate its possible applications in other areas, such as the treatment of sleep apnea and altitude sickness. Almitrine is studied because of its unique ability to selectively stimulate chemoreceptors, offering a potential therapeutic approach for respiratory diseases. Its synthesis involves a complex multi-step process, starting from readily available chemical compounds. However, detailed information on the specific synthetic pathway is not readily available in publicly accessible sources. It is likely that the synthesis process involves the protection of certain functional groups, followed by the formation of the heterocyclic ring structure. The synthetic process is not fully characterized in public domain, and its details are likely proprietary information held by pharmaceutical companies that manufacture almitrine.'

Almitrine: A respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

almitrine : A triamino-1,3,5-triazine compound having allylamino substituents at the 2- and 4-positions and a 4-(bis(p-fluorophenyl)methyl)-1-piperazinyl group at the 6-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID33887
CHEMBL ID1183717
CHEBI ID53778
SCHEMBL ID769301
MeSH IDM0024158

Synonyms (38)

Synonym
D07126
27469-53-0
almitrine (inn)
DB01430
almitrine
2,4-bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
almitrinum [inn-latin]
s 2620
almitrin
einecs 248-475-5
almitrina [inn-spanish]
6-(4-(bis(4-fluorphenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazin-2,4-diamin
1,3,5-triazine-2,4-diamine, 6-(4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)-n,n'-di-2-propenyl-
almitrine [inn:ban]
6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-n,4-n-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
CHEBI:53778 ,
almitrina
almitrinum
n,n'-diallyl-6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-1,3,5-triazine-2,4-diamine
CHEMBL1183717
9a1222nbg4 ,
unii-9a1222nbg4
almitrine [who-dd]
6-(4-(bis(4-fluorophenyl)methyl)1-piperazinyl)-n,n'-di-2-propenyl-1,3,5-triazine-2,4-diamine
almitrine [inn]
almitrine [mi]
DTXSID4057899
SCHEMBL769301
Q-200611
o-acetyl-l-homoserinehydrochloride
6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-2-n,4-n-bis(prop-2-en-1-yl)-1,3,5-triazine-2,4-diamine
n2,n4-diallyl-6-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-1,3,5-triazine-2,4-diamine
FT-0716196
Q4733858
AS-13179
BCP13338
6-{4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}-n2,n4-bis(prop-2-en-1-yl)-1,3,5-triazine-2,4-diamine
EN300-24730401

Research Excerpts

Overview

Almitrine is a drug used in the treatment of hypoxemic chronic lung diseases such as bronchitis and emphysema. It is a potent stimulant of the carotid bodies in human and different animal species that produces a long-lasting enhancement of alveolar ventilation, ameliorating arterial blood gases.

ExcerptReferenceRelevance
"Almitrine is a respiratory analeptic acting on peripherical chemoreceptors. "( [Analysis and criticism of hemodynamic investigations during respiratory analeptic dispensing (author's transl)].
Cupa, M; Daijardin, JB; Hoang, P; Lapandry, C; Pourriat, JL, 1980
)
1.7
"Almitrine bismesylate is a molecule with three components: a di-allylamino-triazine group, a piperazine ring and a bis-parafluoro-benzhydryl fraction."( [The almitrine dimesylate molecule. Various structure-activity relationship aspects].
Labrid, C; Regnier, G, 1984
)
1.5
"Almitrine is a drug used in the treatment of hypoxemic chronic lung diseases such as bronchitis and emphysema because it is a potent stimulant of the carotid bodies in human and different animal species that produces a long-lasting enhancement of alveolar ventilation, ameliorating arterial blood gases. "( Effects of almitrine bismesylate on the ionic currents of chemoreceptor cells from the carotid body.
Canet, E; Gonzalez, C; López-López, JR; Pérez-García, MT, 1998
)
2.13
"Almitrine is a piperazine derivative known to stimulate breathing in the adult but cause apnea in fetal sheep. "( Effects of the respiratory stimulant almitrine on breathing and FOS expression in the brain of fetal and newborn sheep.
Lee, B; Nitsos, I; Walker, DW, 1999
)
2.02
"Almitrine bismesylate is a drug that seems able to improve gas exchange in patients with chronic obstructive pulmonary disease or the adult respiratory distress syndrome."( A comparative study of the effects of almitrine bismesylate and lateral position during unilateral bacterial pneumonia with severe hypoxemia.
Coste, F; Djedaini, K; Dreyfuss, D; Froidevaux, R; Lanore, JJ; Mier, L, 1992
)
1.28
"Almitrine dimesylate is a peripheral respiratory stimulant which is effective both on long and short term treatment of chronic obstructive lung disease. "( [Almitrine: a peripheral respiratory stimulant in chronic obstructive pulmonary disease].
López Alvarez, M; Rubio Terrés, C; Vargas Castrillón, E, 1990
)
2.63
"Almitrine bimesylate is a potent and long-lasting respiratory stimulant in adult species. "( Almitrine mimics hypoxia in fetal sheep with lateral pontine lesions.
Bennet, L; Gluckman, PD; Hanson, MA; Johnston, BM; Moore, PJ, 1990
)
3.16
"Almitrine is a powerful stimulant of chemosensitivity and of the hypoxic ventilatory response in chronic hypoxemia, with potential benefit to patients with chronic air-flow obstruction in respiratory failure."( Almitrine increases the steady-state hypoxic ventilatory response in hypoxic chronic air-flow obstruction.
Cover, D; Hughes, JM; Maxwell, DL, 1985
)
2.43
"As Almitrine bismesylate is a potent peripheral chemo-receptor stimulant we have studied its action, after intra-peritoneal injection, on the intra-neuro-epithelial bodies (NEB) of 24 young rabbits (4 to 17 days old) measuring the intensity of the cytoplasmic fluorescence. "( [Microfluorimetric study of the effect of almitrine bismesylate (Vectarion) on intrapulmonary neuroepithelial bodies].
Lauweryns, JM; van Lommel, A; van Meerbeek, J, 1985
)
1.15
"Almitrine bismesylate is a respiratory agonist which: 1."( Almitrine bismesylate.
Howard, P; Tweney, J, 1987
)
2.44
"Almitrine bismesylate is a peripheral chemoreceptor agonist that improves arterial oxygen tension (PaO2) in patients with COPD during wakefulness."( Long-term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease.
Bachand, RT; Bianco, KA; Cherniack, NS; Gothe, B; Szalkowski, MB, 1988
)
1.32
"Almitrine is an agonist of the chemoreceptors."( Almitrine neuropathy. A nerve biopsy study of 8 cases.
Baudrimont, M; Gherardi, R; Gray, F; Louarn, F, 1987
)
2.44
"Almitrine bismesylate is a chemoreceptor agonist which has been shown to improve arterial blood gas values in chronic obstructive pulmonary disease (COPD) patients, possibly through better ventilation/perfusion matching. "( Long term studies on almitrine bismesylate in COPD patients.
Bourgouin-Karaouni, D; Mercier, J; Prefaut, C, 1986
)
2.03
"Almitrine bismesylate is a peripheral chemoreceptor agonist. "( The carotid body and natriuresis: effect of almitrine bismesylate.
Bardsley, PA; Suggett, AJ, 1987
)
1.98
"Almitrine bismesylate is a pharmacologically unique respiratory stimulant. "( Almitrine bismesylate.
Gotz, VP; Ryerson, GG; Smith, PD, 1987
)
3.16
"Almitrine bismesylate is a new, orally administered, respiratory stimulant that improves arterial blood gas tensions in patients with chronic bronchitis and emphysema, and it may have an effect on the pulmonary circulation and on right ventricular performance. "( A comparison of the effects of almitrine or oxygen breathing on pulmonary arterial pressure and right ventricular ejection fraction in hypoxic chronic bronchitis and emphysema.
Connaughton, JJ; Douglas, NJ; Flenley, DC; Hayhurst, MD; MacNee, W; Muir, AL; Rhind, GB, 1986
)
2

Effects

Almitrine bismesylate has been shown to improve gas exchange in the lungs. Almitrine-raubasine has been used to improve functional rehabilitation after stroke for some time in China.

ExcerptReferenceRelevance
"Almitrine bismesylate has been shown to improve gas exchange in the lungs."( Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study.
Górecka, D; Pachocki, R; Pałasiewicz, G; Sliwiński, P; Zieliński, J,
)
1.24
"Almitrine-raubasine has been used to improve functional rehabilitation after stroke for some time in China."( Stroke and functional rehabilitation: the Chinese experience.
Li, SW, 1998
)
1.02
"Almitrine has potential as a tool for testing the physiological role of the peripheral chemoreceptor. "( The effect of almitrine on the steady-state ventilatory response to carbon dioxide at rest and during exercise in man.
Cummin, AR; Jacobi, MS; Morgan, CN; Patil, CP; Saunders, KB; Telford, RJ, 1990
)
2.08
"Almitrine bismesylate has been thought to provoke peripheral neuropathies in patients with chronic obstructive pulmonary disease (COPD). "( Evolution of peripheral nerve function in hypoxaemic COPD patients taking almitrine bismesylate: a prospective long-term study.
Arnaud, F; David, P; Lerebours, G; Moore, N; Nouvet, G; Ozenne, G; Senant, J, 1987
)
1.95
"Almitrine has significantly improved blood gases in patients with COPD without changing the pulmonary function either at rest or on exercise. "( The effects of almitrine at rest and on exercise in COPD patients.
Feist, H, 1986
)
2.07
"Almitrine bismesylate has been shown to be a respiratory stimulating substance which acts primarily via the peripheral chemoreceptors. "( [Almitrine bismesylate in chronic obstructive lung disease and persistent hypoxemia. Controlled double-blind study with oral administration].
von Wichert, P; Wuttke, R, 1985
)
2.62

Actions

Almitrine produces an increase of PaO2 in arterial blood. This beneficial effect on hypoxemia is potentiated by that of raubasine on microcirculation. Almitrine did not increase the renal potassium excretion.

ExcerptReferenceRelevance
"Almitrine produces an increase of PaO2 in arterial blood, and this beneficial effect on hypoxemia is potentiated by that of raubasine on microcirculation."( [Pharmacological approach to a treatment of senescence and cerebrovascular deficiencies related to hypoxia. Application to 5023 SE].
Devissaguet, M, 1983
)
0.99
"Almitrine induced an increase in PaO2 during wakefulness (p less than .05), an increase in mean SaO2 during sleep (p less than .01) and a decrease in the quantity of desaturation (Qd) during sleep, defined as the product of the mean desaturation by the duration of the episodes of desaturation (p less than .025)."( Effects of almitrine bismesylate on nocturnal hypoxemia in patients with chronic bronchitis and obesity.
Bonsignore, G; Coppola, P; Giannone, G; Macaluso, C; Marrone, O; Milone, F; Oddo, S, 1986
)
1.38
"Almitrine did not increase the renal potassium excretion."( Renal hemodynamics and excretory function of healthy young men during stimulation of their peripheral arterial chemoreceptors by almitrine bismesylate.
Ledderhos, C; Peters, R; Quies, W; Schuster, R, 1987
)
1.2
"Almitrine does not enhance local hypoxic vasoconstriction in the dog."( Influence of alveolar hypoxia on pulmonary vasomotor responses to almitrine in the dog.
Allison, DJ; Goatcher, A; Hughes, JM; Tripathi, A, 1986
)
1.23
"Almitrine produced an increase in PaO2 from 86 +/- 14 (BASELINE) to 129 +/- 69 (ALM 15) and 129 +/- 86 mm Hg (ALM 30)."( Almitrine in acute respiratory failure. Effects on pulmonary gas exchange and circulation.
Alonso, P; López-Messa, JB; Reyes, A, 1987
)
2.44

Treatment

Almitrine treatment of patients with severe COPD and moderate hypoxaemia resulted in a small but significant improvement in PaO(2) over 12 months. More almitrine + raubasine- treated patients' NFDS had improved compared with placebo-treated patients.

ExcerptReferenceRelevance
"Almitrine treatment resulted in PaO(2) improvement of 0.43 +/- 0.88 kPa (3.2 +/- 6.6 mm Hg) (p = 0.003)."( Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study.
Górecka, D; Pachocki, R; Pałasiewicz, G; Sliwiński, P; Zieliński, J,
)
1.24
"Almitrine treatment of patients with severe COPD and moderate hypoxaemia resulted in a small but significant improvement in PaO(2) over 12 months. "( Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study.
Górecka, D; Pachocki, R; Pałasiewicz, G; Sliwiński, P; Zieliński, J,
)
1.96
"More almitrine + raubasine-treated patients' NFDS had improved compared with placebo-treated patients at 2 and 3 months (97 versus 78%, p = 0.013; 100 versus 86%, p = 0.023 respectively)."( Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke.
Li, J; Li, S; Long, J; Ma, Z; Xu, Z; Zhang, Z, 2004
)
1.02
"almitrine for the treatment of hypoxaemia in severe acute respiratory distress syndrome (ARDS)."( Combined nitric oxide inhalation, prone positioning and almitrine infusion improve oxygenation in severe ARDS.
Aigouy, L; Bazin, JE; Cosserant, B; Gillart, T; Guelon, D; Mansoor, O; Schoeffler, P, 1998
)
1.27
"Almitrine treatment results in a significant improvement in PaO2 over that achieved by oxygen alone, an effect that diminishes at high flow rates."( Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.
Evans, TW; Howard, P; Nichol, J; Suggett, AJ; Tweney, J; Waterhouse, JC, 1990
)
2.44

Pharmacokinetics

The effective multiple dose half-life for almitrine bismesylate in plasma is estimated to be 32 days. Almitrine plasma half- life was found to be 116-140 h.

ExcerptReferenceRelevance
" The effective multiple dose half-life for almitrine bismesylate in plasma is estimated to be 32 days."( One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis.
Bachand, RT; Doluisio, JT; Geary, RS; Heilman, R; Macleod, CM; Sebree, TB; Stavchansky, S; Szalkowski, MB,
)
0.69
" In the 4 studies with repeated drug administration, the pharmacokinetic results suggested that a steady state was still not achieved after 9-14 days of treatment."( Study of the pharmacokinetics and pharmacodynamic activity of almitrine bismesylate in infants during the recovery phase following bronchopulmonary dysplasia.
Bonmarchand, M; Bromet, N; Dehan, M; Magny, JF, 1987
)
0.51
" Plasma elimination half-life varies from 45 to 50 hours."( [Clinical pharmacokinetics of almitrine dimesylate].
Bromet, N; Singlas, E, 1984
)
0.56
"Many pharmacokinetic studies have been undertaken following both intravenous and oral administration in diseased patients after acute or chronic administration."( Pharmacokinetics of almitrine bismesylate: studies in patients.
Aubert, Y; Balem, MP; Baune, A; Bromet, N; Courte, S; du Vignaud, P, 1983
)
0.59

Compound-Compound Interactions

Almitrine combined with inhaled nitric oxide (NO) can prevent hypoxia during one-lung ventilation (OLV)

ExcerptReferenceRelevance
"The aim of this study was to assess whether hypoxemia during one-lung ventilation (OLV) can be prevented by inhaled nitric oxide (NO) (Part I) or by its combination with intravenous (IV) almitrine (Part II) in 40 patients undergoing thoracoscopic procedures."( The effects of inhaled nitric oxide and its combination with intravenous almitrine on Pao2 during one-lung ventilation in patients undergoing thoracoscopic procedures.
Castelain, MH; Dalibon, N; Ducros, L; Fischler, M; Kuhlman, G; Liu, N; Moutafis, M, 1997
)
0.72
"min(-1) inhaled prostacyclin in combination with 1 microg."( Effect of inhaled prostacyclin in combination with almitrine on ventilation-perfusion distributions in experimental lung injury.
Dembinski, R; Kuhlen, R; Kurth, R; López, F; Max, M; Rossaint, R, 2001
)
0.56
"Almitrine combined with inhaled nitric oxide (NO) can prevent hypoxia during one-lung ventilation (OLV)."( Low- vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation.
Gallart, L; Minguella, J; Puig, MM; Silva-Costa-Gomes, T; Trillo, L; Vallès, J, 2005
)
2.1

Bioavailability

In healthy subjects, almitrine bismesylate taken orally as tablets is rapidly absorbed from the digestive tract, with an overall bioavailability of about 70%.

ExcerptReferenceRelevance
" Good agreement was obtained between the observed bioavailability parameters and those predicted from the nonlinear fit of the data."( Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans.
Bachand, RT; Doluisio, JT; Geary, RS; Heilman, R; Macleod, CM; Sebree, TB; Stavchansky, S; Szalkowski, MB,
)
0.38
" formulated almitrine bismesylate tablets exceed 85 per cent relative bioavailability with respect to the oral reference solution and are bioequivalent compared to the marketed standard European tablet formulations."( Relative bioavailability of almitrine bismesylate in humans.
Bachand, RT; Doluisio, JT; Geary, RS; Heilman, R; Macleod, CM; Sebree, TB; Stavchansky, S; Szalkowski, MB,
)
0.8
"In healthy subjects, almitrine bismesylate taken orally as tablets is rapidly absorbed from the digestive tract, with an overall bioavailability of about 70%."( [Clinical pharmacokinetics of almitrine dimesylate].
Bromet, N; Singlas, E, 1984
)
0.88

Dosage Studied

In four dose-response studies in three pentobarbital-anesthetized cats, almitrine stabilised blood levels within the therapeutic range of 280-300 ng. In conclusion, only certain individual patients may benefit from a treatment with 100 mg Alm.

ExcerptRelevanceReference
" However, complementary studies using higher dosage of doxapram are warranted."( [Effect of almitrine on arterial gases in patients with chronic respiratory insufficiency. Comparison with doxapram. Preliminary results].
Erven, W; Gepts, L; Marcq, M; Minette, A, 1979
)
0.65
" The sequential dosing scheme stabilised blood levels of almitrine within the therapeutic range of 280-300 ng."( Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease.
Arnaud, F; Bardsley, PA; Empey, D; Harrison, B; Howard, P; O'Reilly, J; Peake, MD; Riordan, JF; Tang, O; Wilkinson, J, 1992
)
0.81
" Almitrine, compared to solvent alone, significantly altered the shape of the dose-response curve to hypoxia."( Almitrine in low dose potentiates vasoconstrictor responses of isolated rat lungs to moderate hypoxia.
Falus, F; Hampl, V; Herget, J, 1991
)
2.63
" In view of the prolonged half life revised dosage schedules are required."( Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale.
Evans, TW; Howard, P; Nichol, J; Suggett, AJ; Tweney, J; Waterhouse, JC, 1990
)
1.72
" Blood samples were taken both at predose and 3 hours postdose at different periods throughout 1 year dosage regimen and plasma levels were analyzed by a GLC method using a nitrogen-phosphorous detector."( One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis.
Bachand, RT; Doluisio, JT; Geary, RS; Heilman, R; Macleod, CM; Sebree, TB; Stavchansky, S; Szalkowski, MB,
)
0.43
" In the first experiment, after equilibration, dose-response curves to Alm (from 0 to 1000 ng/ml, n = 10) were measured under the ventilation with normoxic gas mixture (21% O2, 5% CO2, 74% N2)."( Almitrine bismesylate reduces hypoxic pulmonary vasoconstriction in isolated rat lungs.
Kato, S; Sato, S; Takahashi, K, 1989
)
1.72
" Special dosing schedules may be required."( Almitrine bismesylate.
Howard, P; Tweney, J, 1987
)
1.72
" EEG recordings, psychometric and psychophysiological tests as well as evaluation of pulse, blood pressure and side effects were carried out at 0, 2, 4, 6 and 8 h after the administration of one single dose on day 1 (acute effect), at the 0 h on day 21 (subacute effect) as well as at the 2, 4, 6, and 8 h after one additional superimposed dosage on day 21 (superimposed effect)."( Double-blind, placebo-controlled quantitative EEG and psychometric studies in elderlies on vigilance-promoting effects of an almitrine/raubasine combination (Duxil).
Anderer, P; Grünberger, J; Linzmayer, L; Saletu, B, 1988
)
0.48
" At that dosage level, Duxil may therefore be considered an active treatment of hypoxia associated with old age."( [Effects of 5023 SE on PaO2 at rest in elderly patients with cerebral impairment. A double-blind cross-over trial versus placebo].
Memin, Y, 1983
)
0.27
" It was a double-blind, placebo-controlled, randomized, prospective study which lasted three months and with a dosage regime of 50-100 mg/day of AB."( [Almitrine bismesylate treatment in chronic respiratory insufficiency].
Calatrava, JM; Carreras, J; García-Satué, JL; González Ruiz, JM; Sánchez Agudo, L; Villamor León, J, 1994
)
1.2
" The appropriate and usual dosage (2 tablets per day) and the good tolerance of the compound have been confirmed in a French multicentric study in 5,361 outpatients."( Clinical efficacy of almitrine-raubasine. An overview.
Allain, H; Bentué-Ferrer, D, 1998
)
0.62
" In conclusion, only certain individual patients may benefit from a treatment with 100 mg almitrine whereas the effect of the 75 mg dosage on paO2 did not differ from placebo."( [Almitrine in therapy of chronic obstructive respiratory tract diseases with hypoxemia--a clinical multicenter study comparing 2 dosages].
Magnussen, H; Nowak, D; Wywiol, A, 1998
)
1.43
" Almitrine bismesylate a piperazine derivative improving the ventilation/perfusion matching, used in low dosage and in sequential administration, is a useful drug to increase the PaO2 and so, to delay but not to avoid LTOT in responder patients when PaO2 remains < or = 55 mmHg."( The hypoxaemia in chronic obstructive pulmonary disease (COPD) and its management.
Voisin, C, 1998
)
1.21
"To determine the dose-response relationship of almitrine (Alm) on pulmonary gas exchange and hemodynamics in an animal model of acute lung injury (ALI)."( Dose-dependent effects of almitrine on hemodynamics and gas exchange in an animal model of acute lung injury.
Bubser, HP; Dembinski, R; Falke, KJ; Kaisers, U; Rossaint, R; Sommerer, A, 2000
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
central nervous system stimulantAny drug that enhances the activity of the central nervous system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triamino-1,3,5-triazine
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (476)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990291 (61.13)18.7374
1990's140 (29.41)18.2507
2000's28 (5.88)29.6817
2010's7 (1.47)24.3611
2020's10 (2.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.20 (24.57)
Research Supply Index6.46 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index56.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials130 (25.44%)5.53%
Reviews43 (8.41%)6.00%
Case Studies24 (4.70%)4.05%
Observational2 (0.39%)0.25%
Other312 (61.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium [NCT04357457]Phase 3181 participants (Actual)Interventional2020-09-03Completed
Use of Almitrine in COVID-19 Patients With Acute Respiratory Distress Syndrome Treated by High-flow Nasal Canula Oxygen Therapy [NCT05216575]50 participants (Anticipated)Observational2021-01-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]